$0.60
-0.04(-6.12%)
Mkt Cap $789.2K
$0.56
$3.25
52-Week Range
At a Glance
AI-generatedRevenue was $1.3M (99.2%) Gross Profit was -$2.7M (-357.2%) Operating Income was -$7.5M (12.7%) Net Income was -$8.3M (-273.2%)
Revenue breakdown: License (100%).
6-K
Scinai Immunotherapeutics Ltd. executed a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., extending the option conditions deadline to August 31, 2026, and option exercise period to September 30, 2026, and submitted a revised €12 million non-dilutive FENG SMART Path application for an integrated €15 million R&D program for PC111. The funding, if awarded, would support advancement through human proof of concept while preserving balance sheet flexibility.$789.2K
Market Cap
$1M
Revenue
-$7M
Net Income
Employees31
Fundamentals
How The Business Makes Money
Revenue by Segment
License100%($100.0K)
Activity
Company Profile
CIK0001611747
ISINUS09073Q3039
CUSIP09073Q204
Phone972 8 930 2529
AddressJerusalem BioPark Building, Jerusalem, IL
SEC EDGAR